For patients with acute myeloid leukemia (AML), acquired chromosomal abnormalities present at diagnosis are the most important independent predictors of complete remission, disease-free survival, and overall survival. 1 - 3 Chromosomal analysis
Search Results
Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers
Alison R. Walker and Guido Marcucci
Strategy for Incorporating Molecular and Cytogenetic Markers into Acute Myeloid Leukemia Therapy
Mark G. Frattini and Peter G. Maslak
Edited by Kerrin G. Robinson
classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial . Blood 2001 ; 98 : 1312 – 1320 . 9. Chang C Storer B Scott B . Hematopoietic cell
Acute Myeloid Leukemia: Selecting Induction Therapy Based on Biological Disease Factors
Presented by: Rebecca Olin
For patients with newly diagnosed acute myeloid leukemia (AML), leveraging cytogenetic, fluorescence in situ hybridization (FISH), and molecular genetic data plays a critical role in the selection of induction therapy. At the NCCN 2023 Annual
Addressing Knowledge Gaps in Acute Myeloid Leukemia to Improve Referral for Hematopoietic Cell Transplantation Consultation
Christa Meyer, Lih-Wen Mau, Elizabeth A. Murphy, Ellen M. Denzen, Ellyce Hayes, Darlene Haven, Heather Moore, Jackie Foster, Jaime M. Preussler, and Linda J. Burns
Background Hematopoietic cell transplantation (HCT) is an underused therapy for patients with acute myeloid leukemia (AML). 1 Because HCT is performed only at select hospitals in the United States, it is critical to understand physician referral
Novel Agents for the Treatment of Acute Myeloid Leukemia in the Older Patient
Maria R. Baer and Ivana Gojo
Acute Myeloid Leukemia Incidence Increases With Age The incidence of acute myeloid leukemia (AML) increases with age, with a median age at diagnosis of 67 years. 1 As the proportion of older adults in the population increases, AML in older
Optimizing Therapy for Acute Myeloid Leukemia
Holbrook E. Kohrt and Steven E. Coutre
Dick JE . Acute myeloid leukemia . Hematology Am Soc Hematol Educ Program 2001 : 62 – 86 . 4. Appelbaum FR Gundacker H Head DR . Age and acute myeloid leukemia . Blood 2006 ; 107 : 3481 – 3485 . 5. Leith CP Kopecky KJ
Treatment Updates in Acute Myeloid Leukemia
Presented by: Alexander E. Perl
“In the past few years, the NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Acute Myeloid Leukemia [AML] have had some changes due to new drug approvals. This year, the updates are more incremental than revolutionary, but there
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia
William Alegria, Bernard L. Marini, Kevin Sellery Gregg, Dale Lee Bixby, Anthony Perissinotti, and Jerod Nagel
acute myeloid leukemia (AML) develop severe, prolonged neutropenia after high-intensity induction chemotherapy. 1 , 2 Based on current practice guidelines, this has the potential to result in intravenous antipseudomonal β-lactam exposure for weeks
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Featured Updates to the NCCN Guidelines
Daniel A. Pollyea, Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos de Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Thomas Prebet, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi-Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew Wieduwilt, Kristina M. Gregory, Ndiya Ogba, and Martin S. Tallman
be able to: Integrate into professional practice the updates to the NCCN Guidelines for Acute Myeloid Leukemia Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Acute Myeloid Leukemia Disclosure of
Therapeutic Advances in First-Line Management of Acute Myeloid Leukemia
Daniel A. Pollyea
Introduction From the 1970s until 2017, there was little progress in the frontline treatment of acute myeloid leukemia (AML). Now, according to Daniel A. Pollyea, MD, MS, Associate Professor, University of Colorado School of Medicine, recent drug
